Compare ETN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETN | AZN |
|---|---|---|
| Founded | 1916 | 1992 |
| Country | Ireland | United Kingdom |
| Employees | 101000 | 96100 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.3B | 316.4B |
| IPO Year | 2012 | N/A |
| Metric | ETN | AZN |
|---|---|---|
| Price | $401.22 | $187.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 1 |
| Target Price | ★ $401.95 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 1.9M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | 1.07% | ★ 1.73% |
| EPS Growth | ★ 10.00 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.72 | $10.34 |
| Revenue Next Year | $9.54 | $6.43 |
| P/E Ratio | $188.85 | ★ $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $311.92 | $68.62 |
| 52 Week High | $436.74 | $212.71 |
| Indicator | ETN | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 58.99 |
| Support Level | $355.03 | $180.98 |
| Resistance Level | $408.45 | $191.50 |
| Average True Range (ATR) | 14.19 | 3.13 |
| MACD | 0.35 | 1.19 |
| Stochastic Oscillator | 42.19 | 93.47 |
Founded in 1911 by Joseph Eaton, the eponymous company began by selling truck axles in New Jersey. Eaton has since become an industrial powerhouse largely through acquisitions in various end markets. Eaton's portfolio can broadly be divided into two parts: its electrical and industrial businesses. Its electrical portfolio (representing around 70% of company revenue) sells components within data centers, utilities, and commercial and residential buildings, while its industrial business (30% of revenue) sells components within commercial and passenger vehicles and aircraft. Eaton receives favorable tax treatment as a domiciliary of Ireland, but it generates over half of its revenue within the US.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.